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ABSTRACT
Spinal muscular atrophy (SMA) is a motor neuron
disease. Nusinersen, a splice-switching antisense
oligonucleotide (ASO), was the first approved drug
to treat SMA. Based on prior preclinical studies, both
2′-O-methoxyethyl (MOE) with a phosphorothioate
backbone and morpholino with a phosphorodiami-
date backbone––with the same or extended target
sequence as nusinersen––displayed efficient rescue
of SMA mouse models. Here, we compared the thera-
peutic efficacy of these two modification chemistries
in rescue of a severe mouse model using ASO10-
29––a 2-nt longer version of nusinersen––via sub-
cutaneous injection. Although both chemistries ef-
ficiently corrected SMN2 splicing in various tissues,
restored motor function and improved the integrity of
neuromuscular junctions, MOE-modified ASO10-29
(MOE10-29) was more efficacious than morpholino-
modified ASO10-29 (PMO10-29) at the same molar
dose, as seen by longer survival, greater body-weight
gain and better preservation of motor neurons. Time-
course analysis revealed that MOE10-29 had more
persistent effects than PMO10-29. On the other hand,
PMO10-29 appears to more readily cross an imma-
ture blood-brain barrier following systemic adminis-
tration, showing more robust initial effects on SMN2
exon 7 inclusion, but less persistence in the cen-
tral nervous system. We conclude that both modifi-
cations can be effective as splice-switching ASOs in
the context of SMA and potentially other diseases,
and discuss the advantages and disadvantages of
each.
INTRODUCTION
Antisense oligonucleotides or oligomers (ASOs) are short
synthetic nucleic acid analogs, which bind RNA targets
through Watson–Crick base pairing, resulting in reduced
gene expression or alterations in RNA processing, depend-
ing on their design. Natural nucleic acids are rapidly de-
graded by endogenous nucleases in vivo. Therefore, it is im-
portant to chemically modify oligonucleotides to increase
their resistance to various nucleases, as well as their bind-
ing affinity to RNA targets (1,2). Phosphorothioate (PS)
is a first-generation modification, in which a non-bridging
oxygen is replaced by a sulfur atom in the phosphate
backbone. Although PSmodification significantly increases
ASO half-life in vivo, reflecting increased protein binding
and increased resistance to nuclease cleavage, it reduces the
affinity for the target RNA; moreover, PS-modified DNA
oligonucleotides support RNase H activity (1,2). Second-
generation modifications, such as 2′-O-methyl (2′-O-Me),
2′-O-methoxyethyl (MOE) (3), constrained ethyl (cEt) (4),
and locked nucleic acid (5) further increasemetabolic stabil-
ity of ASOs, as well as the binding affinity for RNA in vivo,
conferring enhanced drug-like properties. Phosphordiami-
date (PDA)morpholino oligomers (PMOs) replace the pen-
tose sugar with a morpholine ring, and the phosphate with
a neutral PDA linkage. PMOs exhibit similar binding affin-
ity to RNA as DNA, have significantly enhanced metabolic
stability as well as low protein binding due to the uncharged
backbone, and do not support RNase H activity (6,7). The
low protein binding feature also makes high-dose PMOs
safer in vivo, compared to other chemistries.
In recent years, ASOs have emerged as a new paradigm
for drug development to treat human diseases. Five ASO
drugs have been approved by the U.S. Food and Drug Ad-
ministration (FDA): fomivirsen, mipomersen, eteplirsen,
nusinersen and inotersen (8–12). Notably, in 2016, two
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ASOs were approved to treat neuromuscular diseases:
eteplirsen, a morpholino oligomer that was conditionally
approved in the US to treat Duchenne muscular dystro-
phy (DMD), and nusinersen, an MOE/PS-modified ASO,
which was approved in the US, and subsequently in Europe
and other areas, to treat spinal muscular atrophy (SMA)
(9–11,13). Both drugs work through redirecting pre-mRNA
splicing, but in opposite directions: eteplirsen restores the
reading frame of theDMD gene that carries various frame-
shifting mutations or deletions, by promoting exon 51 skip-
ping (13), whereas nusinersen increases expression of func-
tional SMN protein from the SMN2 gene by promoting
exon 7 inclusion (14,15).
SMA is a fatal genetic disorder that manifests during
infancy or childhood, with an incidence of approximately
one in 10 000 live births (16,17). It is caused by deletion
or mutation of survival of motor neuron 1 (SMN1), a gene
that encodes the essential and ubiquitously expressed pro-
tein SMN. Low levels of this protein result in degenera-
tion of spinal-cord motor neurons and consequent atro-
phy of skeletal muscles (18). All animal species possess only
one Smn gene, and the homozygous knockout is embryonic
lethal; humans, however, have an additional SMN2 gene
that expresses the same SMNprotein, albeit in low amounts
(18,19). Compared to SMN1, there are two key nucleotide
transitions in SMN2––C6T in exon 7, and to a lesser de-
gree G-44A in intron 6––which cause skipping of exon 7
in approximately 90% of SMN2 transcripts (20,21). The re-
sulting SMN7 protein isoform is unstable and rapidly de-
graded. The small amount of full-length (FL) protein ex-
pressed by SMN2 is not sufficient to compensate for the loss
of SMN1. SMApatients have two ormore copies of SMN2,
and the copy number is inversely correlated with the age of
disease onset and its severity (22). Nusinersen (previously
called ASO10-27), is 18-nt long, and prevents the binding
of hnRNP A1/A2 repressor proteins to a splicing silencer
(ISS-N1) near the 5′ splice site of SMN2 intron 7, thereby
efficiently correcting SMN2 splicing in vivo (23–28).
Clinical trials demonstrated the effectiveness of
MOE/PS-modified nusinersen (29–31). PMOs that
target the same ISS-N1 region showed marked efficacy in
SMA mouse models, correcting SMN2 splicing, amelio-
rating symptoms and extending the lifespan (32,33). We
previously showed that nusinersen is more potent than
morpholino/PDA-modified ASO10-29––a 2-nt longer
version––in correcting SMN2 splicing in the central
nervous system (CNS) of an SMA mouse model after
ICV bolus injection, likely due to enhanced accumulation
and/or slower clearance of nusinersen in this compart-
ment (34). However, to date, no thorough head-to-head
comparison of the efficacy of the two modifications with
respect to antisense splicing therapy in SMAmouse models
has been performed, and therefore, it is unclear if one
of the modifications might be more advantageous for
SMA therapy. Published studies do not allow for a direct
comparison, because the ASOs employed differ not only
in chemistry, but also in length, administration route and
dose, and different mouse models were used. Addressing
this issue may help design or optimize ASO drugs for
treating SMA as well as other diseases.
In this study, we compared the efficacy of MOE/PS and
morpholino/PDA chemistries using ASO10-29 in the se-
vere Taiwanese SMA mouse model; we refer to these two
ASOs as MOE10-29 and PMO10-29, respectively. Consid-
ering that peripheral delivery of nusinersen reaches theCNS
before postnatal maturation of the murine blood-brain bar-
rier (BBB) and strongly rescues a severe SMAmouse model
(25,26), we focused on subcutaneous (SC) administration
in neonate mice and comprehensively assessed the effects of
the two ASOs on SMN2 splicing in various tissues and on
phenotypic rescue. The two ASOs were delivered at early
postnatal days at the same molar doses. We found that
MOE10-29 outperformed PMO10-29 in improving the phe-
notype, including a more robust survival increase. This re-
sult is consistent with MOE10-29’s more persistent effects
on SMN2 splicing in all peripheral tissues, which indicate
that MOE10-29 has a longer pharmacodynamic half-life
than PMO10-29, though the initial effect of PMO10-29 on
SMN2 splicing is similar or slightly better. On the other
hand, PMO10-29 appears to more readily cross the imma-
ture BBB into the CNS, based on splicing analysis; how-
ever, its effect in the CNS is short-lived. We conclude that
bothMOE-PS and morpholino chemistries are effective for
splice-switching ASOs to treat SMAmice, though the latter
may require higher doses ormore frequent dosing to achieve
similar phenotypic rescue.
MATERIALS AND METHODS
Oligonucleotide synthesis
The synthesis and purification of MOE10–29 (5′-
ATTCACTTTCATAATGCTGG-3′) with PS backbone
and 5-methyl cytosines were performed as described (24).
PMO10-29 (5′-ATTCACTTTCATAATGCTGG-3′) was
purchased from Gene Tools (Philomath, OR, USA). All
oligonucleotides were dissolved in 0.9% saline.
Animals and drug delivery
All mouse protocols were in accordance with Cold Spring
Harbor Laboratory’s Institutional Animal Care and Use
Committee guidelines. The initial breeding pairs of hu-
man SMN2 transgenic mice were purchased from Jack-
son Laboratory (stock number 005058), and were origi-
nally developed by Hsieh-Li et al. (35). The severe SMA
model (Smn−/−; SMN22TG/0) was generated as previously
described (25). The oligonucleotide solutions were injected
subcutaneously into the upper back with a 5-l syringe and
a 33-gauge custom removable needle (Hamilton).
Radioactive RT-PCR
Mouse tissues were pulverized in liquid N2 with mortar and
pestle, and total RNA was extracted with Trizol (Invitro-
gen). One microgram of total RNAwas reverse-transcribed
with ImProm-II Reverse Transcriptase (Invitrogen). For
radioactive RT–PCR, the human-specific primer pair E4-
33to55-F and E8-15to36-R was used for amplifying human
SMN2 transcripts in RNA samples from mouse tissues, as
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described (25); all PCR products were labeled with -32P-
dCTP and analyzed by 6% native polyacrylamide gels, fol-
lowed by phosphorimage analysis. The extent of exon 7 in-
clusion was calculated as described (25), and the signal in-
tensity of each cDNAband was normalized according to its
G+C content.
Western blotting
Twenty milligrams of each mouse tissue was pulverized
in liquid N2 and homogenized in 0.4 ml of protein sam-
ple buffer containing 2% (w/v) sodium dodecyl sulphate
(SDS), 10% (v/v) glycerol, 50 mM Tris–HCl (pH 6.8) and
0.1 M DTT. Protein samples were separated by 12% SDS-
polyacrylamide gel electrophoresis and electro-blotted onto
nitrocellulose membranes. The membranes were blocked
for 2 h with 5% (w/v) non-fat milk in Tris-buffered saline
containing 0.05% Tween-20 (TBST), and then incubated
overnight at 4◦Cwith primary antibodies: monoclonal anti-
SMN (BD Biosciences, 1:500) and anti--tubulin (Sigma).
After washing with TBST for three times, the membranes
were incubated with secondary IRDye 700CW-conjugated
goat anti-mouse or anti-rabbit antibody. Protein signals
were detected with an Odyssey instrument (LI-COR Bio-
sciences).
Histology
Spinal cords were fixed with 4% (v/v) formaldehyde in
phosphate-buffered saline overnight. For gem counting
in motor neurons and motor-neuron counting in lumbar
spinal-cord segments L1–L2, paraffin-embedded 6-mm sec-
tions were treated with citrate buffer for antigen retrieval,
and incubated with goat anti-ChAT antibody (Millipore)
and/or mouse SMN antibody (BD Bioscience) followed by
donkey anti-goat Alexa fluor 568 (Invitrogen) and/or don-
key anti-mouse Alexa fluor 488 secondary antibodies. For
neuromuscular junction (NMJ) staining, mice were anaes-
thetized by intraperitoneal injection of Nembutal (sodium
pentobarbital; 50mg/kg) or ketamine/xylazine (100mg/kg
ketamine/10 mg xylazine) and transcardially perfused with
PBS and then 4% paraformaldehyde. After 24 h post-fixing,
the tibialis anterior (TA) and flexor digitorum brevis 2/3
(FDB-2/3) muscles were dissected and teased into layers
5–10 fibers thick to facilitate penetration of antibodies, in-
cluding anti-neurofilament (1:2000; Chemicon) and anti-
synaptophysin (1:200, Invitrogen) antibodies. Acetylcholine
receptors (AChRs) were labeled with Alexa Fluor 555-
conjugated -bungarotoxin (-BTX, Invitrogen). Confocal
immunofluorescence imaging was done with an LSM710
confocal microscope (Carl Zeiss) by merging Z-stacks of
multiple planes into one image.
Motor-function tests
Grip strength was measured using a grip-strength meter
(Columbus Instruments) as described (26). Rotarod tests
were carried out with aRotaRodIV instrument (AccuScan);
the rotation was set at a constant rate of 5 rpm in one di-
rection for a maximum of 180 s. Among five trials for each
mouse, the longest time that the mouse stayed on the rod
was recorded.
Statistical analysis
Differences between sets of data were analyzed by two-
tailed Student’s t test using SPSS16.0 (IBM); a value of P
< 0.05 was considered statistically significant. In all of the
figures, data are expressed as mean ± SEM.
RESULTS
Systemically administered MOE10-29 outperforms
PMO10-29 in improving the phenotype of SMA mice
To compare the efficacy of MOE10-29 and PMO10-29, we
used the severe Taiwanese mouse model, which has a mean
survival of 10 days. Efficient rescue of this model requires
SMN restoration in peripheral tissues (25,26). Therefore,
we delivered these two ASOs by SC injection. Newborn
pups were given two injections between postnatal day 0
(P0) and P1 at two doses: 4 and 12 nmol/g/injection, cor-
responding to 32 and 95 mg/kg/injection respectively for
MOE10-29, and 27 and 81 mg/kg/injection, respectively,
for PMO10-29. The higher dose was expected to generate
robust rescue based on previous studies (25,32). Each group
had 12 mice (six female and six male mice). As expected,
treatment with either MOE10-29 or PMO10-29 dramati-
cally improved survival and showed dose-dependent effects;
however,MOE10-29 had a better therapeutic outcome than
PMO10-29. The low dose of MOE10-29 increased the me-
dian and mean survival to 139 and 152 days, respectively,
compared with 89 and 98 days, respectively, for the low
dose of PMO10-29 (Figure 1A). In addition, we observed
that some low-dose PMO10-29-treated mice suddenly died,
without showing any obvious signs of disease morbidity,
such as weight loss and tissue necrosis, whereas this only
rarely occurred in MOE10-29-treated mice. Similarly, high-
doseMOE10-29 improved themedian andmean survival to
197 and 233 days, respectively, whereas high-dose PMO10-
29 improved the median and mean survival to 183 and 204
days, respectively (Figure 1A). These data indicate that sys-
temic administration of MOE10-29 is more effective in ex-
tending the lifespan of SMA mice at the doses tested.
Body weight gain, which is severely impaired in the
mouse model, was also monitored weekly for up to 14
weeks. The average body weight of mice in the three groups
all plateaued at ∼21 g at 11 weeks post-treatment, ex-
cept for the high-dose MOE10-29 group, in which treated
mice reached 26 g in body weight at the 14th week post-
treatment, representing a 24% increase compared with the
other groups (Figure 1B and C).
Tissue necrosis is a characteristic feature in mild SMA
mice, which typically begins to show at the fourth week af-
ter birth. Extending the lifespan of severe SMA mice to
>3 weeks by drug treatment allows necrosis to appear, and
the poorer the rescue, the more severe the necrosis. Necro-
sis generally occurs in the tail and ear pinnae, but can also
extend to the nose, limbs and anus (25,36). After treat-
ment with either MOE10-29 or PMO10-29 at either dose,
all mice exhibited tail necrosis, and the earliest occurrence
was at ∼6 weeks (Figure 1C and D). The tail necrosis in
both high-dose groups was much less severe than in the
low-dose groups (Figure 1D). Interestingly, the process of
necrosis was much slower in MOE10-29-treated mice than
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Figure 1. MOE10-29 led to better therapeutic outcomes than PMO10-29 in severe SMA mice. (A) Survival curves after two SC injections of saline (n =
12), MOE10-29 (4 nmol/g, n = 14; 12 nmol/g, n = 14) and PMO10-29 (4 nmol/g, n = 14; 12 nmol/g, n = 14) between P0 and P1. (B) Body-weight curves
after SC injections of MOE10-29 and PMO10-29 as in (A). (C) Representative pictures of high-dose MOE10-29- and PMO10-29- treated SMA mice on
P60. (D) Tail length was measured weekly for up to 14 weeks (n = 12). (*) P < 0.05 high dose versus low dose of the same ASO; (#) P < 0.05 versus all
other groups.
in PMO10-29-treated mice. When necrosis started from the
tail tip, it took 3–5 weeks for MOE10-29-treated mice to
completely lose the tail, whereas it took less than a week,
and often just 2–3 days, for PMO10-29-treated mice to lose
the tail (Figure 1D). These data indicate that MOE10-29 is
more efficacious and appears to have a longer duration of
effect in preventing tissue necrosis, compared to PMO10-29.
ASO effects on exon 7 inclusion in peripheral tissues
The differences in therapeutic outcomes after treatment
with the two ASOs should reflect their respective capabil-
ities in correcting SMN2 splicing in affected tissues. Some
recent studies showed that multiple peripheral tissues, such
as heart and liver, are critical in the pathogenesis of SMA, at
least in severe mouse models (25,37–40). We first examined
SMN2 splicing changes in peripheral tissues, including the
liver, heart, kidney andmuscle, at three time points (P7, P15
and P30) after treatment with four different doses (4, 12, 18
and 21 nmol/g) of the two ASOs (Figure 2 and Supplemen-
tary Figure S1). Both ASOs, at all doses, promoted exon
7 inclusion in all examined tissues. The PMO appeared to
have a faster onset of action, as its effects in all tissues 7 days
after injection were higher than those of the MOE ASO
in the low-dose groups (Figure 2 and Supplementary Fig-
ure S1). By 15 days, however, their effects became similar.
Skeletal muscle was a favorable target tissue for PMO10-29,
resulting in stronger splicing correction on P7 at all tested
doses, compared to MOE10-29. In the higher-dose groups,
the splicing changes on P7 and P15 were similar for the
two oligomers. However, by P30, the percentage of exon 7
inclusion in all tissues in the high-dose PMO10-29 group
decreased; in contrast, mice in the high-dose MOE10-29
group maintained a higher level of exon 7 inclusion in all
examined peripheral tissues, compared to all other groups.
These data highlight that the effects ofMOE10-29 are more
sustained than those of PMO10-29 in these tissues (Figure
2 and Supplementary Figure S2). Interestingly, except for
the liver, the percentage of exon 7 inclusion in the heart,
skeletal muscles, and kidneys of mice treated with high-dose
MOE10-29 increased over time, which is likely due to both
the sustained effects of the MOE oligomer, and improve-
ment in SMN2 splicing with age during the first postnatal
month, as seen in untreated heterozygous mice (Figure 2
and Supplementary Figure S3).We also performedwestern-
blotting analysis, and observed the corresponding changes
in full-length SMN protein levels in these tissues in ASO-
treated mice (Figure 3).
Systemically delivered PMO10-29 penetrates more readily
into the CNS than MOE10-29
Our previous studies showed that systemically adminis-
trated ASOs can cross the immature BBB in neonatal mice
and reach CNS tissues (25,26). Therefore, we compared the
effects of the two ASOs on SMN2 splicing in the CNS af-
ter SC injection. RNA samples from brain and spinal cord
tissues were isolated on P7, P15 and P30, after two SC in-
jections of each ASO at 4, 12, 18 or 21 nmol/g between P0-
P1. Radioactive RT-PCR was performed to analyze SMN2
exon 7 inclusion (Figure 4 and Supplementary Figure S1).
Interestingly, PMO10-29 treatment enhanced SMN2 exon
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Figure 2. SMN2 splicing changes in mouse peripheral tissues after SC injection of MOE10-29 or PMO10-29. Splicing analysis of liver (A and B), heart
(C andD), kidney (E and F) and muscle (G andH) tissues fromMOE10-29- and PMO10-29-treated mice by radioactive RT-PCR at three time points (P7,
P15 and P30) after treatment as in Figure 1 (n = 4). (*) P < 0.05 high dose versus low dose of the same ASO. % incl, percentage of exon 7 inclusion; (#) P
< 0.05 MOE versus PMO at the same dose.
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Figure 3. SMN protein expression in mouse peripheral tissues after SC injection of MOE10-29 or PMO10-29. Western blotting analysis of SMN levels
in mouse liver (A and B), heart (C and D), kidney (E and F) and muscle (G and H) tissues at three time points (P7, P15 and P30) after the treatments
described in Figure 1 (n = 4). (*) P < 0.05 high dose versus low dose of the same ASO; (#) P < 0.05 MOE versus PMO at the same dose.
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Figure 4. SMN2 splicing changes in mouse CNS tissues after SC injection of MOE10-29 or PMO10-29. Splicing analysis of spinal cord (A and B) and
brain (C andD) fromMOE10-29- and PMO10-29-treated mice by radioactive RT-PCR at three time points (P7, P15 and P30) after treatment as in Figure
1 (n = 4). (*) P < 0.05 high dose versus low dose of the same ASO; (#) P < 0.05 MOE versus PMO at the same dose.
7 inclusion in the CNS on P7 and P15 more robustly than
MOE ASO treatment. However, from P7 to P30, the exon
7 inclusion levels in the PMO10-29 groups decreased in the
spinal cord (65% for low dose and 82% for high dose) and
brain (64% for low dose and 88% for high dose), whereas
mice treated with high-dose MOE10-29 showed sustained
high levels of exon 7 inclusion (Figure 4 and Supplementary
Figure S2), suggesting thatMOE10-29 has a longer half-life
than PMO10-29 not only in peripheral tissues, but also in
theCNS. Immunoblotting revealed similar changes in SMN
protein levels in the spinal cord and brain, corresponding to
the mRNA level changes in all ASO-treated groups (Figure
5). These results demonstrate that PMO10-29 crosses the
immature BBBmore readily thanMOE10-29, but the effect
of MOE10-29 in the CNS lasts longer.
Gem counts in the spinal cord
SMN protein is localized in the cytoplasm and in a subnu-
clear structure termed gemini of Cajal body, or gem (41).
Gem numbers positively correlate with cellular SMN lev-
els (42). Therefore, we examined gem numbers in spinal-
cord motor neurons on P9, after ASO treatment as above.
Amonoclonal anti-SMN antibody was used to detect SMN
in the ventral horn of lumbar segments L1–L2, with choline
acetyltransferase (ChAT) being used to label motor neu-
rons. As shown in Figure 6, both MOE10-29- and PMO10-
29-treated SMAmice hadmore gems inmotor neurons than
untreated SMAmice, with increases of 1.8- (lowMOE), 3.4-
(high MOE), 2.0- (low PMO) and 2.7-fold (high PMO), re-
spectively. This was reflected by increases in both the num-
ber of cells with gems and the number of gems per cell (Fig-
ure 6C). Paradoxically, in spite of the higher SMN pro-
tein levels in the spinal cord of PMO10-29-treated mice,
the number of gems in motor neurons in the high-dose
MOE group wasmarkedly higher than that in the high-dose
PMO10-29 group (Figure 6). The cause of this apparent dis-
crepancy is currently unknown, but may reflect differences
in the uptake of ASOs with each chemistry in different cell
types.
Spinal-cord motor-neuron counts and motor-function tests
Motor-neuron degeneration is the hallmark of SMA. To
count motor neurons, we used ChAT staining to label the
cells in sections of lumbar segments L1–L2 derived from
SMAmice onP9, after treatmentwithMOE10-29, PMO10-
29 or saline control. As expected, untreated (saline control)
SMA mice had a strikingly low number of motor neurons
in the spinal cord, compared to heterozygotes, with a re-
duction of 50% (Figure 7A). In contrast, mice treated with
ASOs showed a marked increase in the number of ChAT-
positive cells, with an increment of 38% (low MOE), 62%
(high MOE), 31% (low PMO) and 31% (high PMO), re-
spectively (Figure 7A and B). These results indicate that
MOE10-29 is more effective in rescuing motor neurons.
The marked increase in motor-neuron counts in high-dose-
MOE10-29-treated mice over high-dose-PMO-treated mice
is consistent with the above gem-counting data, support-
ing the notion that motor neurons may favor MOE/PS
modification over morpholino/PDA, in terms of sponta-
neous ASO uptake. We next measured motor function in
ASO-treated mice using grip-strength and rotarod tests at
3 months old. There were no significant differences in grip
strength and rotarod tests in mice treated with the same
dose of MOE10-29 and PMO10-29 (Figure 7C and D).
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Figure 5. SMN protein expression in mouse CNS tissues after SC injection of MOE10-29 and PMO10-29. Western blotting analysis of SMN levels in
mouse spinal cord (A and B) and brain (C and D) tissues at three time points (P7, P15 and P30) after treatment as in Figure 1 (n = 4). (*) P < 0.05 high
dose versus low dose of the same ASO; (#) P < 0.05 MOE versus PMO at the same dose.
Some low-dose-ASO treated mice died within 24 h after the
behavioral experiments.
Structural analysis of the neuromuscular junction (NMJ)
Defects in NMJs, such as denervation, immature end-
plates, and poor terminal arborization are typical in SMA
mouse models. Earlier studies showed that severe dener-
vation occurs selectively in axial and appendicular mus-
cles, and FDB-2/3 are the most severely affected muscles
in SMA mouse models (43,44). We examined NMJ struc-
tures in FDB-2/3 and TA muscles on P9. We used anti-
synaptophysin and anti-neurofilament antibodies to label
presynaptic nerve terminals, and -bungarotoxin to la-
bel postsynaptic endplates. The extent to which the NMJ
pathology can be rescued byASO treatment is an important
parameter to evaluate the efficacy of ASO drugs. Similar to
what was previously reported, SMAmice displayed smaller
endplate sizes and less complexity (reflected by the number
of perforations per NMJ), in comparison to heterozygous
mice (Figure 8 and Supplementary Figure S4). After treat-
ment with MOE10-29 or PMO10-29, the endplate size in
FDB-2/3 muscles increased by 33% (lowMOE), 80% (high
MOE), 46% (low PMO) and 80% (high PMO), respectively,
and the percentage of NMJs containing ≥ 2 perforations
increased by 44, 52, 13 and 40%, respectively, compared to
severe SMA mice (Figure 8B and C).
Denervated NMJs were defined as -BTX-labeled end-
plates without overlapping synaptophysin-stained axons,
and partial denervation was defined as ≤50% occupancy
of presynaptic nerve terminals in an endplate. After ASO
treatment, the percentage of fully and partially denervated
NMJs in FDB-2/3 muscles decreased by 35% (low MOE),
42% (high MOE), 22% (low PMO) and 45% (high PMO),
compared to untreated mice (Figure 8A and D). There was
also a marked NMJ improvement, similar between the two
ASO treatments, in TAmuscles (Supplementary Figure S4).
Based on the immunostaining analysis of NMJs, we con-
clude that both ASOs have similar efficacy in rescuing the
NMJ pathologies of SMA mice. The lack of differences be-
tween the two ASOs in NMJ recovery may reflect the early
time point (P9) selected for the analysis.
DISCUSSION
MOE and morpholino are two chemistries that are fre-
quently used to modify ASOs for clinical applications (45–
47). Nusinersen, the first approved therapeutic for SMA,
uses the MOE/PS modification and demonstrated robust
efficacy in both preclinical and clinical studies (25–26,29–
31). PMOs also showed high effectiveness in preclinical
SMA mouse models (32,33). In the present study, we thor-
oughly compared these two chemical modifications in the
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Figure 6. Gem counts in motor neurons of spinal cord segments L1–L2 obtained from ASO-treated SMA mice. (A) SMA mice were SC injected twice
with saline (n = 4), MOE10-29 (4 nmol/g, n = 4; 12 nmol/g, n = 4) and PMO10-29 (4 nmol/g, n = 4; 12 nmol/g, n = 4) between P0 and P1. Tissues were
collected on P9. Gems and motor neurons were labeled with SMN and ChAT; nuclei were counterstained with DAPI. (B) Quantitation of gems per 100
motor neurons from (A). (C) Percentages of motor neurons containing 0, 1, 2, 3, or ≥4 gems from A. (*) P < 0.05 high dose versus low dose of the same
ASO; (#) P < 0.05 MOE versus PMO at the same dose.
context of identical-sequence 20-mer ASOs, in a severe
SMA mouse model.
Antisense effect of MOE10-29 is more persistent
By measuring SMN2 splicing, we found that although
PMO10-29 initially displayed a robust effect in promoting
exon 7 inclusion in all tested tissues, which was similar to,
or on occasion stronger than that of MOE10-29, its effects
were not as long-lasting as those of MOE10-29. The fact
that MOE10-29 has a longer half-life in vivo than PMO10-
29 is likely the main reason why MOE10-29 is therapeuti-
cally more effective. Our conclusion is consistent with and
extends our previous work, which showed that ICV bo-
lus injection of PMO10-29 resulted in less accumulation in
CNS tissues compared to nusinersen (ASO10-27) (34).
The approval of nusinersen to treat SMA was a ma-
jor milestone in the history of oligonucleotide therapeu-
tics, which is becoming an important platform for new drug
discovery. The resurgence of oligonucleotide therapeutics is
largely attributable to advances in chemical modifications.
However, there have been few comparative studies of ASO-
modifying chemistries.Nearly two decades ago, Sazani et al.
developed an elegant EGFP-transgenic mouse model to
assay for splice-switching antisense activity with several
chemical modifications, includingMOE/PS and PMO (48).
EGFP is expressed in this model only when an effective
ASO is administered to block inclusion of a pseudo-exon in
a chimeric minigene comprising the EGFP coding sequence
interrupted by amutated intron 2 of humanHBB (-globin)
(48,49). The authors examined EGFP expression one day
after intraperitoneal injection of ASOs for four consecu-
tive days at 50 mg/kg/day; based on the EGFP readout,
MOE/PS had similarly high antisense activity in some tis-
sues as PMO, while outperforming PMO in other tissues;
overall, our results are consistent with these data, demon-
strating that both modifications can be employed for de-
veloping therapeutic ASOs (48). Recently, Prakash et al.
also compared MOE10-29 versus PMO10-29 in the liver of
transgenic SMA mice, and found that both modifications
had similar effects in correcting SMN2 splicing (50), which
is also consistent with our data (Figure 2). However, the pre-
vious studies did not examine the duration of the effects, a
key parameter in drug development. In addition, the com-
parisons in previous studies all used the same mass doses,
instead of molar doses and morpholino-modified ASOs
have ∼15% lower molecular weights; thus, the effects of
morpholino-modified ASOs were slightly over-estimated.
Unique features of each modification
One interesting observation about PMO10-29 is its con-
sistent superiority over MOE10-29 in antisense activity in
skeletal muscle in the first week after systemic injection
(Figure 2 and Supplementary Figure S1). This observation
suggests that morpholino-modified ASOs are more read-
ily taken up by skeletal muscle fibers. This feature may
give morpholino ASOs an edge for treating skeletal-muscle
disorders. On the other hand, the charge-neutral and hy-
drophobic nature, poor protein binding and lower molecu-
lar weight of PMO10-29 may explain why it crosses an im-
mature BBB of neonatal mice more readily than MOE10-
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Figure 7. Motor-neuron counts in spinal cord segments L1–L2 and motor-function tests of SMA mice. (A) SMA mice were treated with saline (n = 4),
MOE10-29 (4 nmol/g, n= 4; 12 nmol/g, n= 4) and PMO10-29 (4 nmol/g, n= 4; 12 nmol/g, n= 4) as described in Figure 6. Untreated heterozygous mice
(Het, n= 13) were used as normal controls. Tissues were collected on P9. Motor neurons and nuclei were labeled with ChAT and DAPI. (B) Motor-neuron
number was calculated based on (A) (four mice per group and three counts per mouse). (C and D) Grip strength and rotarod tests of rescued SMA mice
(n = 12) at 3 months of age. (*) P < 0.05 high dose versus low dose of the same ASO; (#) P < 0.05 MOE versus PMO at the same dose.
29, as shown by SMN2 splicing in the first two weeks post-
treatment (Figure 4). However, this feature of morpholino
may be of little significance in terms of ASO therapy, as nei-
ther MOE nor morpholino ASOs, typically 18–20mer long,
can cross an intact BBB in older animals.
Interestingly, although systemic PMO10-29 resulted in
greater CNS penetration, the gem counts on P9 revealed
more gems inmotor neurons fromMOE10-29-treatedmice.
One explanation for this observation is that motor neu-
rons in particular may favor internalization of ASOs with
MOE/PS chemistry over PMO. Alternatively, the PS chem-
istry itself may play a role in the increase in gem numbers
in motor neurons of MOE10-29-treated mice. Recent stud-
ies revealed that PS-modified ASOs induce the formation of
some cytoplasmic and subnuclear non-membranous struc-
tures through binding to their protein components (51,52).
Further experiments will be necessary to clarify the mecha-
nism, which may be of therapeutic relevance.
Therapeutic outcomes and caveats to this comparative study
Administration routes have a big impact on drug efficacy.
We previously showed that systemic delivery of nusinersen
via SC or intraperitoneal injection robustly rescued SMA
mouse models, whereas ICV delivery displayed moderate
rescue, indicating that peripheral defects are critical in the
mouse models (25,26). Perhaps due to SMN restoration
in the CNS being less important in the mouse model, we
did not observe significant differences in rescue, particu-
larly of the mean survival, between the two modifications
when ASOs were injected ICV (Supplementary Figure S5).
Yet all PMO10-29-treated mice survived no longer than 86
days, whereas three MOE10-29-treated mice survived over
86 days (98, 149 and 255 days, respectively), consistent with
our conclusion that MOE ASOs have more sustained ac-
tivities. However, the therapeutic outcomes by ICV-injected
ASOs cannot be solely explained by their effects in the
CNS, because ASOs are gradually cleared from the CNS
into the blood and distributed to peripheral tissues. Poren-
sky et al. demonstrated that 8 nmol/g PMO10-29 delivered
ICV increased the full-length SMN2 transcript 2-fold in the
liver (32); therefore, excessive doses of PMO in the CNS
are safe, but phenotypic improvement is likely dominated
by peripheral effects. A different animal model that has
CNS-restricted defects would be useful to precisely compare
chemical modifications for ASO applications in the CNS.
In this study, we focused on comparing the therapeu-
tic outcome by systemic delivery of the two ASOs, and
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Figure 8. NMJ staining of the flexor digitorum brevis 2 and 3 (FDB-2/3) muscles of SMAmice. (A) SMAmice were treated with saline (n= 4), MOE10-29
(4 nmol/g, n= 4; 12 nmol/g, n= 4) and PMO10-29 (4 nmol/g, n= 4; 12 nmol/g, n= 4) as in Figure 6. Untreated heterozygous mice (Het, n= 4) were used
as normal controls. FDB-2/3 were collected on P9 and stained for neurofilament with anti-neurofilament (blue), nerve terminals with anti-synaptophysin
(green) and motor endplates with -bungarotoxin (-BTX, red). (B) NMJ area was measured from (A) (four mice per group and three counts per mouse).
(C) Quantification of perforations identified by -BTX, based on (A) (4 mice per group and 3 counts per mouse). (D) Percentages of innervated endplates
(red), partially denervated endplates (blue), and fully denervated endplates (white) were quantitated based on (A) (four mice per group and three counts
per mouse). (*) P < 0.05 high dose versus low dose of the same ASO; (#) P < 0.05 MOE versus PMO at the same dose.
found that at equivalent concentrations,MOE10-29-treated
mice displayed a stronger phenotypic improvement than
PMO10-29, including greater body-weight gain, slower
necrosis of distal tissues, higher motor-neuron counts and
importantly, longer survival. Therefore, we conclude that at
the samemolar dose,MOE/PS is amore effective chemistry
for therapy in a severe SMA mouse model.
On the other hand, the initial effect of PMO10-29 on
SMN2 splicing in all tissues is no less than that of MOE10-
29, suggesting that more frequent dosing with PMO10-
29 may achieve comparable if not better therapeutic out-
come, compared to the two-injection dosing schedule with
MOE10-29. In theory, each ASO should be dosed at in-
tervals optimally suited to its respective pharmacokinetics.
However, from a clinical perspective, nusinersen is given by
lumbar puncture, which is burdensome, and it would be de-
sirable to reduce the dosing frequency, rather than increase
it. Indeed, a new clinical trial, DEVOTE, is testing higher
nusinersen doses, in part with the hope that fewer lumbar
punctures will be needed. Thus, a more realistic strategy
would be to increase the dose per injection.
One important aspect in drug development is the toxicity
issue. We previously reported significant toxicity of nusin-
ersen after one ICV injection of >15 g in newborn SMA
mice, whereas PMO10-29 displayed no toxicity after one
ICV injection of 81 g (27,32). On the other hand, we did
not observe any toxicity when nusinersen was ICV-infused
into the CNS of adult mice at 150 g/day for a week (53).
Currently, nusinersen is used clinically at 12mg per intrathe-
cal injection, four times in the first 2 months, and every 4
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months thereafter, and no drug-related toxicities have been
observed, although some patients have been treated contin-
uously for up to 7 years. PMOs are less toxic due to their
chemical properties and more rapid excretion. It is possi-
ble or even likely that comparable efficacy can be achieved
with higher doses of PMO, but this would add to the costs
of manufacture and treatment. We do believe that PMOs,
considering their unique features, may be a good choice to
treat certain diseases.
To date, at least six chemistries have been tested to mod-
ify ASO10-27 or its shorter or longer versions for therapeu-
tic potential. 2′-F-modifiedASO10-27 inhibits SMN2 splic-
ing, due to recruitment of IFL2 and IFL3 near the 5′ splice
site of intron 7 by the 2′-F/RNA duplex (54), resulting in
exon 7 skipping, and therefore, this modification cannot be
used to treat SMA. 2′-O-Me-modified ASOs efficiently cor-
rect SMN2 splicing in cultured cells, but they are ineffec-
tive in mouse models and cause CNS inflammation when
centrally delivered (28,34,53,55). Robin et al. recently re-
ported a tricyclo-DNA (tcDNA) ISS-N1-targeting 15mer
ASO that corrected SMN2 splicing and halted tissue necro-
sis in a mild mouse model (56). However, the tcDNA ASO
has yet to be further characterized and tested in more severe
models. We previously assessed a cEt version of nusinersen,
which carriesmixedMOE/cEtmodifications with amelting
temperature 15◦C higher than nusinersen, in SMA fibrob-
lasts and SMN2-transgenic mice; both ASOs had similar
potency for SMN2 splicing correction, suggesting that cEt
also has therapeutic potential, but further increase in the
affinity of nusinersen for binding to its target did not in-
crease its potency (34). MOE and morpholino are the only
twomodifications of ASOs that have been tested in multiple
mouse models, including mild and severe ones and showed
high efficacy in SMN2 splicing correction and phenotypic
rescue.
Here, our rigorous comparative study with the two ASOs
at the same molar dose established that MOE-PS outper-
formed morpholino in the context of a severe SMA mouse
model. The observation that MOE-PS ASO activity re-
mains high not only in the liver, but also in all other exam-
ined peripheral tissues, one month following a high-dose of
MOE10-29 suggests that ASO therapeutics can be used to
treat a broad spectrum of diseases. Morpholino oligomers
likely require higher doses and/or more frequent dosing
to achieve comparable efficacy. As novel ASO-modification
chemistries continue to emerge, a new modification or a
combination of different chemistries could potentially re-
sult in even greater efficacy and tolerability for various ap-
plications.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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